Targets › CHRNA1
6 programs from 5 companies in 13 trials: 5 Phase 4, 5 Phase 2, 3 Phase 1; Other, Oncology, Respiratory; next expected readout Dec 2026.
[Isoform 1]: Upon acetylcholine binding, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane..; FUNCTION: [Isoform 2]: Non functional acetylcholine receptor alpha subunit which is not integrated into functional acetylcholine-gated cation-selective channels. (UniProt, P02708)
Open in Phaseline: the race on CHRNA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The University of Texas Health Science Center, Houston | ALA 10% gel Muscle-type nicotinic acetylcholine receptor antagonist | HCRTR2, HCRTR1, CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE, HTR2A, PTGS2, PTGS1 | Phase 4 | Anesthesia; Cleft Lip and Palate; Pancreatic Ductal Adenocarcinoma (PDAC); Stimulant Use Disorder … | Dec 2026 |
| The University of Texas Medical Branch, Galveston | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Post Operative Pulmonary Complications | Dec 2026 |
| Nordsjaellands Hospital | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Tracheal Intubation | Apr 2027 |
| The University of Texas Health Science Center, Houston | Suxamethonium Muscle-type nicotinic acetylcholine receptor agonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 4 | Anesthesia | – |
| Memorial Sloan Kettering Cancer Center | Rocuronium Muscle-type nicotinic acetylcholine receptor antagonist | CHRNA1, CHRNG, CHRNB1, CHRND, CHRNE | Phase 2 | Prostate Cancer | Jan 2027 |
| COUR Pharmaceutical Development Company | CNP-106 Antigenic AChR peptide pool (AChRα and AChRε peptides) delivered in PLGA polymer particles | CHRNA1, CHRNE | Phase 1 | Myasthenia Gravis | – |
Anesthesia (2) Post Operative Pulmonary Complications (1) Prostate Cancer (1) Myasthenia Gravis (1) Tracheal Intubation (1) Cleft Lip and Palate (1) Pancreatic Ductal Adenocarcinoma (PDAC) (1) Stimulant Use Disorder (1) Bipolar II Disorder (1) Bronchopulmonary Dysplasia (1) Onychomycosis of Toenail (1) Neuropsychiatric Syndromes (1)
small molecule (6)
The University of Texas Health Science Center, Houston (2) The University of Texas Medical Branch, Galveston (1) Memorial Sloan Kettering Cancer Center (1) COUR Pharmaceutical Development Company (1) Nordsjaellands Hospital (1)
CHRNE (6) CHRNG (5) CHRNB1 (5) CHRND (5) HCRTR2 (1) HCRTR1 (1) HTR2A (1) PTGS2 (1) PTGS1 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.